Abstract
AbstractSafety clinicians have a wealth of resources describing how to perform signal detection. Nevertheless, there are some nuances concerning approaches taken by regulatory authorities and statistical considerations that should be appreciated. New approaches, such as the FDA Medical Queries, illustrate the value of considering medical concepts over individual adverse events. One area which would benefit from further clarity is how safety signals may be evaluated for evidence of a causal relationship to the drug of interest. Just as such safety signals can take many forms, the types of tools and methods required to interrogate these signals are equally as diverse. An understanding of the complexity of this process can aid the safety reviewer in successfully characterizing the emerging safety profile of a drug during the pre-marketing phase of development.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference29 articles.
1. van Manen RP, Fram D, DuMouchel W, et al. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf. 2007;6(4):451–64.
2. Perez C, Olivier P, Lortal B, et al. Detection of drug safety signals from clinical trials data: role of SUSARs. Pharmacol Res. 2018;131:218–23.
3. Zink RC, Marchenko O, Sanchez-Kam M, et al. Sources of safety data and statistical strategies for design and analysis: clinical trials. Ther Innov Reg Sci. 2018;52:141–58.
4. Buchanan J, Li M, Ni X, Wildfire J. A new paradigm for safety data signal detection and evaluation using open-source software created by an interdisciplinary working group. Ther Innov Reg Sci. 2021;55:1214–9.
5. Doan T, Lievano F, Bhattacharya M, Scarazzini L, Renz C. In: Doan T, Lievano F, Bhattacharya M, Scarazzini L, Renz C, editors. Pharmacovigilance: a practical approach. Amsterdam: Elsevier; 2019.